Frontiers in Oncology最新文献

{"title":"Pulmonary sarcomatoid carcinoma coexisting with tuberculosis: a case report and literature review.","authors":"Zhi-Hao Huang, Yu-Fei Zhu, Yun-Yun Zeng, Hui-Yi Huang, Jia-Qi Liu, Wen-Chang Cen, Shan Su","doi":"10.3389/fonc.2024.1492574","DOIUrl":"10.3389/fonc.2024.1492574","url":null,"abstract":"<p><p>Pulmonary sarcomatoid carcinoma (PSC) is a rare non-small-cell lung cancer with sarcomatous components or sarcomatoid differentiation, high degree of malignancy, and insensitivity to chemotherapy or radiotherapy. The management of PSC coexisting with tuberculosis (TB) poses a greater challenge, as it necessitates concurrent administration of both anti-TB and anti-neoplastic therapies. The efficacy of anti-PD-1 immunotherapy in non-small-cell lung cancer is promising, but its safety in patients with co-existent TB remains uncertain. Here, we describe a case of advanced PSC coexisting with TB, which experienced progression-free survival (PFS) of over 36 months after receiving anti-TB and anti-neoplastic therapy composed of chemotherapy, vascular targeting therapy, and PD-1 inhibitors simultaneously. The patient is still being followed up with a satisfactory quality of life. This paper is focused on the characteristics and treatment of PSC and discuss the clinical strategies of lung cancer coexisting with TB.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1492574"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study.","authors":"Jingtian Shen, Xi Wang, Olivier Mpano, Ying Wang, Yihan Shan, Xinning Lou, Piaopiao Ye, Xiaojian Yan","doi":"10.3389/fonc.2024.1504084","DOIUrl":"10.3389/fonc.2024.1504084","url":null,"abstract":"<p><strong>Objective: </strong>To compare the effects of different treatment modes containing PARPis and traditional treatment modes on the survival of patients with recurrent ovarian cancer.</p><p><strong>Methods: </strong>From December 2012 to December 2023, 131 recurrent ovarian cancer patients were screened. The patients were followed up retrospectively, and the relevant data was collected and analyzed.</p><p><strong>Results: </strong>Eighty-three patients used PARPis throughout the treatment process, and the median OS was not reached. Forty-eight patients did not use PARPis, and the median OS was 45.4 months. The two groups ' BRCA gene status, NACT, postoperative residual disease status, and PFI differ (<i>P</i> < 0.05). There was no significant difference in recurrence characteristics between the PARPis use and non-use groups in first-line maintenance therapy (<i>P</i> < 0.05). The use of PARPis, CA125 level and PFI were the independent influencing factors of OS in patients with recurrent ovarian cancer (<i>P</i> < 0.05). The median OS of patients with PARPis maintenance treatment in the single-line, second-line and last-line has not been reached. The median OS in the multi-line group was 69.5 months.</p><p><strong>Conclusion: </strong>The use of PARPis, CA125 level and PFI were independent influencing factors of OS in patients with recurrent ovarian cancer. The first-line maintenance use of PARPis will not cause differences in disease recurrence characteristics. Compared with the patients without PARPis, patients with recurrent ovarian cancer receiving PARPis maintenance therapy have longer OS. The group of patients with PARPis maintenance treatment in the second and last lines showed better OS (<i>P</i> < 0.05). However, OS was not significantly different between the second-line and last-line groups (<i>P</i> < 0.05). There was no significant difference in OS between the multiple-line use PARPis and single-line use PARPis groups.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1504084"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level.","authors":"Zhiqiang Zhang, Mengfan Xu, Muhan Shang, Zhiqi Liu, Lei Yang, Dexin Yu","doi":"10.3389/fonc.2024.1395301","DOIUrl":"10.3389/fonc.2024.1395301","url":null,"abstract":"<p><strong>Background: </strong>Penile metastasis originating from prostate cancer is an extremely rare condition, typically associated with a poor prognosis. Therapeutic approaches are not well established and may require individualized adaptation based on clinical assessment. Radiotherapy is commonly utilized to alleviate symptoms. For patients presenting with priapism, palliative penectomy is often recommended.</p><p><strong>Case presentation: </strong>This report describes a case of penile metastasis from prostate cancer in a 74-year-old man who presented with priapism. Positron emission tomography/computed tomography (PET/CT) imaging identified metastases in the penis, along with multiple metastatic sites in the lungs, left iliac vascular lymph nodes, abdominal and pelvic lymph nodes, and bones. A palliative penectomy was performed to relieve symptoms, and postoperative pathology confirmed the presence of penile metastasis originating from prostate cancer. Following the penectomy, the patient received ongoing androgen deprivation therapy (ADT) along with androgen receptor antagonists (enzalutamide).</p><p><strong>Conclusions: </strong>Penile metastasis from prostate cancer is a rare condition and is often initially misdiagnosed due to the presentation of occult malignancy. This case highlights the need for clinicians to enhance their understanding and diagnostic accuracy regarding penile metastases. Imaging techniques such as Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography (Ga-68 PSMA PET/CT) can detect prostate cancer lesions even at low serum prostate-specific antigen (PSA) levels, thereby improving diagnostic precision for prostate cancer.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1395301"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of PARPi re-maintenance therapy for recurrent ovarian cancer.","authors":"Yulin Wang, Yunjie Yang, Binghong Guo, Xiaoyan Li, Renakezi Tuersun, Ye Cao, Jundong Li, Jihong Liu, Su Li, Tao Liu, Yongwen Huang","doi":"10.3389/fonc.2024.1512339","DOIUrl":"10.3389/fonc.2024.1512339","url":null,"abstract":"<p><strong>Objective: </strong>The current clinical data regarding the re-administration of PARPi maintenance therapy in platinum sensitive recurrent ovarian cancer (PSROC) is limited. This study aims to investigate the efficacy and associated factors of PARPi re-maintenance therapy in PSROC patients in China.</p><p><strong>Methods: </strong>In this study, there were 201 patients with PSROC who had received maintenance therapy previously and achieved complete or partial response after platinum-based chemotherapy upon recurrence. The re-maintenance therapy group (Re-PARPi) and chemotherapy alone group (Chem-A) were categorized based on whether PARPi was reused after recurrence chemotherapy. A propensity-score matching (PSM) analysis was conducted between re-maintenance therapy group (Re-PARPi-P) and chemotherapy alone group(Chem-A-P)to adjust for imbalanced risk factors. The efficacy was evaluated via progression-free survival (PFS) and prognostic factors were also analyzed.</p><p><strong>Results: </strong>In the PSM subgroup, the median PFS (mPFS) of Re-PARPi-P group (44 cases) and Chem-A-P (44 cases) group were 10.0 months and 6.5 months (HR 1.64, P=0.041) respectively, confirming that re-maintenance therapy was superior to relapse chemotherapy alone. The mPFS was 10.8 months in all patients in the Re-PARPi group (51 cases), with 11.0 months in BRCAm group and 10.2 months in BRCAwt group (P=0.806). Intervals of more than 6 months between two PARPi therapies might improve the efficacy of PARPi re-treatment (mPFS 11.2 months vs. 7.8 months, HR 3.94, P=0.005). Age, BRCA status, number of previous treatment lines, CA125 level prior to re-administration, and other factors were not significantly related to the efficacy of re-maintenance therapy. Patients with a frameshift mutation (p. Ile1824Aspfs3) in the C-terminal domain of BRCA1 germline gene had significantly better efficacy with PARPi re-treatment compared to other groups. Only nonsense mutation (p.Gln1037, p.Cys328, p.Leu1072) occur in BRCA germline gene with re-treatment with PARPi might be suboptimal. The incidence of PARRi re-treatment interruption was 3.9%.</p><p><strong>Conclusion: </strong>PARPi re-maintenance therapy in PSROC might improve prognosis compared to chemotherapy alone, regardless of their genetic mutation status. Patients with re-maintenance therapy might benefit if the interval between the use of PARP inhibitors exceeded 6 months. The structural domains of BRCA mutations with different sensitivity to PARPi might serve as a promising biomarker for optimizing treatment. Re-treatment with PARPi was well-tolerated.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1512339"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11758227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative fever after elective minimally invasive resection for gastric and colorectal cancer: incidence, risk factors and characteristics.","authors":"Fan He, Chenglin Tang, Fuyu Yang, Dongqin Zhao, Junjie Xiong, Yu Zou, Defei Chen, Guoquan Huang, Kun Qian","doi":"10.3389/fonc.2024.1413041","DOIUrl":"10.3389/fonc.2024.1413041","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the incidence and risk factors of postoperative fever (POF) in gastrointestinal cancer (GIC), discuss the influence of POF on short-term clinical outcomes, and predict anastomotic leakage (AL) based on POF characteristics.</p><p><strong>Methods: </strong>Overall, 1362 patients that underwent radical resection for GIC were retrospectively analyzed. POF was defined as a postoperative temperature ≥38°C during hospitalization. Patients were divided according to whether they experienced POF. The influence of POF on short-term clinical outcomes was analyzed using propensity score matching. A subgroup analysis was conducted to examine the relationship between different POF characteristics and AL or infection-related complications.</p><p><strong>Results: </strong>POF occurred in 172 patients (12.6%). Overall, 115 patients (66.9%) had fever ≥38.6°C, while 105 (61.0%) had fever at postoperative day (POD) 2, and 73 (42.4%) had POF multiple times. Multivariate analysis showed that patients with a preoperative albumin level < 37 g/L (odds ratio [OR]=1.57, p=0.016), operative time >195min (OR=1.55, p=0.020), and radical gastrectomy (OR=1.84, p=0.009) were more likely to develop POF. Compared to patients without fever, drainage tube indwelling time, duration of antibiotic use, and hospital stay were prolonged, while AL and infection-related complications were more common in patients with POF. POF ≥38.6°C (OR=1.74, p=0.039) and PCT >0.7 ng/mL (OR=2.99, p=0.022) at POD 3 were early predictors of AL.</p><p><strong>Conclusion: </strong>POF was closely related to preoperative albumin levels, operative time, and type of operation, and it delayed postoperative recovery in patients with GIC. And POF ≥38.6°C and PCT >0.7 ng/mL at POD 3 were independent predictors of AL.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1413041"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11759314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative circulation predict prolonged length of stay after head and neck free flap reconstruction: a retrospective study based on machine learning.","authors":"Zhongqi Liu, Jinbei Wen, Yingzhen Chen, Bin Zhou, Minghui Cao, Mingyan Guo","doi":"10.3389/fonc.2024.1473447","DOIUrl":"10.3389/fonc.2024.1473447","url":null,"abstract":"<p><strong>Background: </strong>Head and neck free flap reconstruction presents challenges in managing intraoperative circulation, potentially leading to prolonged length of stay (PLOS). Limited research exists on the associations between intraoperative circulation and PLOS given the difficulty of manual quantification of intraoperative circulation time-series data. Therefore, this study aimed to quantify intraoperative circulation data and investigate its association with PLOS after free flap reconstruction utilizing machine learning algorithms.</p><p><strong>Methods: </strong>804 patients who underwent head and neck free flap reconstruction between September 2019 and February 2021 were included. Machine learning tools (Fourier transform, et al.) were utilized to extract features to quantify intraoperative circulation data. To compare the accuracy of quantified intraoperative circulation and manual intraoperative circulation assessments in the PLOS prediction, predictive models based on these 2 assessment methods were developed and validated.</p><p><strong>Results: </strong>Intraoperative circulation was quantified and a total of 114 features were extracted from intraoperative circulation data. Quantified intraoperative circulation models with a real-time predictive manner were constructed. A higher area under the receiver operating characteristic curve (AUROC) was observed in quantified intraoperative circulation data models (0.801 [95% CI, 0.733-0.869]) compared to manual intraoperative circulation assessment models (0.719 [95% CI, 0.641-0.797]) in PLOS prediction.</p><p><strong>Conclusion: </strong>Machine learning algorithms facilitated quantification of intraoperative circulation data. The developed real-time quantified intraoperative circulation prediction models based on this quantification offer a potential strategy to optimize intraoperative circulation management and mitigate PLOS following head and neck free flap reconstruction.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1473447"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757266/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CA19-9-related macrophage polarization drives poor prognosis in HCC after immune checkpoint inhibitor treatment.","authors":"Tingting Du, Jialin Zou, Yunying Yang, Honghui Xie, Hui Pang, Wenquan Zhuang, Shutong Wang, Guangyan Wei","doi":"10.3389/fonc.2024.1528138","DOIUrl":"10.3389/fonc.2024.1528138","url":null,"abstract":"<p><strong>Background: </strong>Elevated levels of carbohydrate antigen 19-9 (CA19-9) levels are known to worsen outcomes in various tumors by influencing immune responses. However, the role of CA19-9 in immunotherapy for hepatocellular carcinoma (HCC) remains poorly understood.</p><p><strong>Methods: </strong>This study included 621 patients treated with anti-PD-1/PD-L1 treatment at the First Affiliated Hospital of Sun Yat-sen University from January 2017 to March 2023. During immunotherapy, CA19-9 levels were measured and classified as either elevated (≥35 U/mL) or normal (<35 U/mL) for clinical analysis.</p><p><strong>Results: </strong>Patients with elevated CA19-9 levels had significantly worse progression-free survival (PFS) and overall survival (OS). The 1-year and 2-year PFS rates were 53.3% and 29.1% in the normal CA19-9 group compared to 16.9% and 11.3% in the elevated group (<i>p</i> < 0.001). Similarly, the 1-year and 2-year OS rates were 90.5% and 75.5% in the normal group versus 64.0% and 36.5% in the elevated group (<i>p</i> < 0.001). Multivariate analysis confirmed CA19-9 was an independent prognostic factor for both PFS and OS. Bioinformatic analysis indicated that FUT3, a key gene in CA19-9 synthesis, correlated with increased macrophage infiltration. And increased M2 macrophage levels and reduced M1 macrophage levels were noted in HCC samples with elevated CA19-9 levels. Further <i>in vivo</i> experiments indicated blocking CA19-9 improved the efficacy of PD-1 treatment through inducing the M1-like polarization of macrophages.</p><p><strong>Conclusions: </strong>Our findings demonstrate that elevated CA19-9 levels during immunotherapy are associated with poor survival outcomes in HCC patients. These findings highlight the crucial role of CA19-9 in shaping the tumor immune environment, particularly through its effect on macrophage polarization, and suggest that targeting CA19-9 may improve immunotherapy outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1528138"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>Helicobacter pylori</i>-induced gastric cancer on gastrointestinal microbiota: a narrative review.","authors":"Mohsen Heidary, Sousan Akrami, Tohid Madanipour, Nafiseh Hosseinzadeh Shakib, Marzie Mahdizade Ari, Masoumeh Beig, Saeed Khoshnood, Roya Ghanavati, Monireh Bazdar","doi":"10.3389/fonc.2024.1495596","DOIUrl":"10.3389/fonc.2024.1495596","url":null,"abstract":"<p><p><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection is a typical microbial agent that interferes with the complex mechanisms of gastric homeostasis by disrupting the balance between the host gastric microbiota and mucosa-related factors, ultimately leading to inflammatory changes, dysbiosis, and gastric cancer (GC). We searched this field on the basis of PubMed, Google Scholar, Web of Science, and Scopus databases. Most studies show that <i>H. pylori</i> inhibits the colonization of other bacteria, resulting in a less variety of bacteria in the gastrointestinal (GI) tract. When comparing the patients with <i>H. pylori-</i>positive and <i>H. pylori</i>-negative GC, the composition of the gastric microbiome changes with increasing abundance of <i>H. pylori</i> (where present) in the gastritis stage, whereas, as the gastric carcinogenesis cascade progresses to GC, oral and intestinal-type pathogenic microbial strains predominate. <i>H. pylori</i> infection induces a premalignant milieu of atrophy and intestinal metaplasia, and the resulting change in gastric microbiota appears to play an important role in gastric carcinogenesis. The effect of <i>H. pylori</i>-induced GC on GI microbiota is discussed in this review.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1495596"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of radiobiological models for local control prediction in lung cancer patients treated with stereotactic body radiation therapy.","authors":"Bao-Tian Huang, Pei-Xian Lin, Ying Wang, Li-Mei Luo","doi":"10.3389/fonc.2024.1431140","DOIUrl":"https://doi.org/10.3389/fonc.2024.1431140","url":null,"abstract":"<p><strong>Background: </strong>The debate regarding the accuracy of radiobiological models for local control (LC) prediction in lung cancer patients undergoing stereotactic body radiation therapy (SBRT) remains unresolved. The study seeks to externally validate the predictive efficacy of radiobiological models using single-institutional SBRT database.</p><p><strong>Methods: </strong>The cohort comprised 153 patients diagnosed with primary or metastatic lung cancer who underwent SBRT. The study employed three radiobiological models to estimate the probability of 2-year LC, including the Liu model, Klement model, and Ohri model. Furthermore, the likelihood of 3-year LC was predicted using the Liu model, Klement model, Gucken model, and Santiago model. The performance of the prediction models was assessed through the AUC values of the receiver operating characteristic (ROC) curve and the calibration plots.</p><p><strong>Results: </strong>Local recurrence was observed in 38.6% of patients (59/153) within two years, and in 43.1% (66/153) within three years after the radiotherapy. The ROC curves indicated discriminative power for all the 2-year and 3-year models, with the exception of the Klement model. The Ohri model showed a significantly improved discriminative ability than the Klement model for 2-year prediction, while it was not statistically significant when compared to the Liu model. However, no significant differences were found among the four models in terms of 3-year LC prediction. The calibration plots, using the Hosmer-Lemeshow goodness-of-fit test, confirmed that the predicted probabilities of the models were in agreement with the actual observation with <i>P</i>>0.05, except for the 2-year LC prediction using the Klement model.</p><p><strong>Conclusion: </strong>Considering the balance between prediction accuracy and model simplicity, it is recommended to utilize the Ohri model for 2-year LC prediction and either the Gucken model or Santiago model for 3-year LC prediction.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1431140"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11788688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143122673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of the combination of anlotinib and envafolimab in the treatment of unresectable or metastatic liposarcoma: findings from a single-center retrospective study.","authors":"Hongliang Liu, Qisheng Hao, Xi Wang, Mengxing Cheng, Fabo Qiu, Bin Zhou","doi":"10.3389/fonc.2024.1502945","DOIUrl":"10.3389/fonc.2024.1502945","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of anlotinib combined with envafolimab in the treatment of unresectable or metastatic liposarcoma.</p><p><strong>Methods: </strong>This single-center, retrospective study enrolled 15 patients with unresectable or metastatic liposarcoma, who were treated at the Retroperitoneal Tumor Surgery Research Center of Qingdao University Affiliated Hospital between April 2022 and November 2023. The treatment regimen consisted of anlotinib combined with envafolimab. Treatment efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1. Treatment-related adverse events (TRAEs) were assessed using Common Terminology Criteria for Adverse Events version 5.0.</p><p><strong>Results: </strong>A total of 15 patients with unresectable or metastatic liposarcoma were included; among them, seven were male (46.7%) and eight were female (53.3%), with a median age of 55 years. The pathological subtype distribution was as follows: three (20.0%) patients with well-differentiated liposarcoma, 11 (73.3%) patients with dedifferentiated liposarcoma, and one (6.7%) patient with myxoid liposarcoma. At 12 weeks post-diagnosis, none of the patients achieved a complete response. The objective response rate was 6.7%, with one patient (6.7%) achieving a partial response. Disease stability was observed in 10 (66.6%) patients, which corresponded to a disease control rate of 73.3%. Disease progression occurred in four (26.7%) patients. The median follow-up time was 16.9 months and the median progression-free survival time was 14.2 months. Seven patients experienced TRAEs, of whom three (42.2%) had grade 3-4 TRAEs. The most common TRAEs were liver function abnormalities, hypertension, and fatigue.</p><p><strong>Conclusion: </strong>Anlotinib combined with envafolimab demonstrates promising efficacy and manageable safety in treating unresectable or metastatic liposarcoma.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1502945"},"PeriodicalIF":3.5,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11757892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}